EN DE
Watch DarioHealth Corp for free: we tell you when fair value or trend changes.
Data-driven stock valuation

DarioHealth Corp (DRIO) fair value: what the stock is really worth

As of Nov 10, 2026: fair value (intrinsic value) of DarioHealth Corp stock $2.40, price $2.39, upside +0.4%, quality 44 out of 100. Rating: fairly valued. The value is an estimate: none of our valuation models currently carries, it draws on revenue and assets compared with similar companies. Updated daily.

  1. Keep an eye on it?Free in your watchlist: 5 stocks without an account, 10 with one Yes, for free

Healthcare US

DC DarioHealth Corp logo Thin data Nov 10, 2026

DarioHealth Corp

DRIO · US
Fairly valued, weak quality

The stock costs about what our calculation considers fair.

Low debt
Fair value $2.40 · Fairly valued
Quality 44/100
Insiders bought $100,000 (6M)
Weak Growth (revenue 3y −6.8 %/yr in USD)
Loss-making · -169.9% net margin (TTM)
Negative free cash flow
Trails peers (2/9)
Narrow moat 10/100 · thin data
Thin data
Estimate
Watch DarioHealth Corp for free: we tell you when fair value or trend changes. Watch for free

What runs behind every stock

26 valuation models 8 families, DCF to NCAV 37 quality factors margins, balance sheet, cashflow, debt 6 AI factors moat, what no ratio measures 2,000+ data points verified, per stock, median

69 individual criteria per stock, every one traceable See the method →

Price vs Fair Value

$380.40 $2.06 Fair Value $2.40 Aug 2021 Nov 2026

White line = price, green steps = our fair value per fiscal year. As of Nov 10, 2026.

How to read this chart

60‑month range $2.06 – $380.40 · fair‑value band $1.80 – $2.99 · the $2.39 price screens below the $2.40 fair value. As of Nov 10, 2026.

Follow DarioHealth in your weekly email

Every Wednesday you see whether DarioHealth is on track or worth a review, plus price against fair value. Free, up to 3 stocks.

We send you a confirmation link. Unsubscribe with one click.

Which stocks are undervalued right now? Check free Discover now →

Company profile

DarioHealth Corp. operates as a digital health company in the United States and internationally.

Show moreShow less

Its digital therapeutics platform and suite of solutions deliver personalized and dynamic interventions driven by data analytics and one-on-one coaching for diabetes, hypertension, weight management, musculoskeletal pain, and behavioral health.

The company offers Dario Connect, a solution used to create communities around specific health conditions to increase awareness and education; Dario Mind, a behavioral health offering that decreases the symptoms of stress, anxiety, and depression; Dario Move, focuses on improving posture to alleviate pain with medical device; and Dario Health, a self-care application and virtual coaching platform for diabetes, hypertension, and weight management and GLP-1. It also provides bundled full-suite or partial-suite subscriptions.

The company was formerly known as LabStyle Innovations Corp. and changed its name to DarioHealth Corp. in July 2016. DarioHealth Corp. was incorporated in 2011 and is based in New York, New York.

Stock analysis

DarioHealth Corp (DRIO) currently trades at $2.39, while our estimate is $2.40, so the stock looks roughly fairly valued today (gap 0.4%).

Show more

Valuation

None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Scenario range: $1.80 (bear) to $2.99 (bull), the price of $2.39 sits inside it. Bear and bull are the same models on cautious and optimistic assumptions, a range, not a price target.

Quality & growth

The Quality Score stands at 44/100 (below-average quality), in the Healthcare sector.

Weak Growth: Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.

DarioHealth Corp reported revenue of $22.4M in FY2025 versus $20.5M in FY2021, a compound +2.2%/yr. Reported net income was −$41.7M in FY2025.

Key figures

Market cap $32.4M Micro · P/S ratio 1.54 · EPS (TTM) $−2.28 · Return on equity −59.9% · Return on assets (EBIT) −52.7% (5-year average) · Operating margin −125% · Revenue (TTM) $21.0M · Revenue growth (YoY) −3.6%.

Competitive moat

Our AI-assisted moat analysis scores the competitive advantage at 10 out of 100 (low confidence).

What moves the price

The share trades about 83% below its 52-week high and 16% above its 52-week low, currently below its 200-day average.

For context, the median of 10 Healthcare peers we cover trades at −35% fair-value upside, at 0%, DRIO screens cheaper than that median.

Fair Value

Bear $1.80 Fair Value $2.40 Bull $2.99
Price $2.39 · Upside +0.4%
Estimate. None of our valuation models currently carries for this company, usually because of losses or heavy investment. The estimate draws on revenue and assets compared with similar companies and is less precise than a model-based fair value.

Quality Score breakdown

Overall quality 44/100

It rates the business: profits, how they develop, real cash, balance sheet, investing and share count.

Profitability 5
How much profit the company makes from its sales and capital
Quality Growth 34
Are margins and returns getting better?
Cashflow 3
Do the profits arrive as real cash?
Financial strength 62
Debt, balance sheet and risk of trouble
Investment 100
Does it invest with discipline instead of growing at any price?
Low Volatility 24
How calm the share price moves, does not count
Price momentum 2
Price momentum of the last 3 to 12 months, does not count
Near the 52-week high 1
Distance to the 52-week high, does not count
New shares 100
Buys back shares or issues new ones?

Open the full quality analysis →

Insider trades

In the last 6 months, one officer or director bought shares worth $100,000, on Jul 23, 2026.

  • BuyDennis MatheisDirector14,430 shares at $6.93$100,000Jul 23, 2026

Plus 8 other filings such as grants, option exercises or tax withholding. They are not market purchases or sales.

Sales are often planned (taxes, diversification, 10b5-1 plans). Purchases with their own money are seen as the stronger sign. For information only: not part of the quality score or Fair Value.

Source: SEC Form 4, as of Nov 10, 2026. All filings at the SEC ↗

Revenue & earnings trend

Growth Quality ⓘGrowth is valuable only when reinvestment earns attractive returns (Aswath Damodaran): sustainable growth depends on return on capital, reinvestment and efficiency. Basis: total company revenue over the periods shown on the cards (3Y/5Y/all years), not per share, so a merger can show up as a growth jump; per-share earnings growth is in the value-creation card. 29/100
Revenue growth is inconsistent: the periods point in different directions, so there is no trend to rely on.
Revenue growth 1 year
−17.3%
Revenue growth 3 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
−6.8%
Revenue growth 5 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+24.2%
Start year 2020 (pandemic). Over 10 years: +39.1% a year
Revenue growth 11 years ⓘMeasures the company's TOTAL revenue from reported annual statements: compound average growth per year (CAGR) from the fiscal year 3, 5 or N years back to the most recent comparable fiscal year. Not per share: buybacks do not change this number, and a merger can appear as a growth jump. Per-share growth (which does include buybacks) is in the value-creation card.
+73.8%
Profit margin (trend) ⓘOperating margin then vs now, from reported annual statements. A falling margin after a boom year is the classic peak-earnings signal: the growth rate then leans on an inflated base.
−394.7% (2020) → −163.9% (2025)
What shareholders gained per year ⓘWe only publish this rate when it is defensible. Reason: fiscal 2025 is a loss year, no rate is defined from a loss
not computed

Watch DRIO, get fair value alerts →

Compare DarioHealth Corp with another stock

Price, fair value, quality and upside side by side.

Free, no sign-up

Peer GroupⓘHow this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.Health Information Services · 141 stocks

Beats the industry median on 2/8 measures
Overall it trails its industry peers.
Valuation
Quality Score 44 · Below median
Fair Value upside +0.4% · Above median
Profitability
Return on assets −37.9% · Bottom 25%
Net margin (12 months) −169.9% · Bottom 25%
Operating margin (12 months) −125.2% · Bottom 25%
Growth and dividend
Revenue growth (quarter YoY) −3.6% · Bottom 25%
Balance sheet
Debt / equity 0.45× · Highest 25%

Valuation Multiplesvs Health Information Services median · lower = cheaper

P/B 0.48× · book value is mostly goodwill ⓘGoodwill and other intangible assets are larger than the equity. The book value mainly reflects prices paid for past acquisitions, so we do not rank this P/B against the peer group.
P/S (12 months) 1.55× · Cheaper than median

Strength profile in five axes (Snowflake)

VALUEFUTUREPASTHEALTHDIVIDEND
This stock
VALUEFUTUREPASTHEALTHDIVIDEND
Sector peers
VALUE (fair-value potential)34 · sector 13
FUTURE (revenue growth)0 · sector 45
PAST (return on equity)0 · sector 0
HEALTH (low debt)77 · sector 98
DIVIDEND (yield)0 · sector 46

Context: sector, industry, market

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

None of the checked exposures detected

Similar stocks

10 more Health Information Services stocks, each showing price versus our Fair Value estimate.

Stock Price Fair Value vs Fair Value Compare
Doximity, Inc DOCS $32.42 $36.16 +12% vs DRIO
Veeva Systems Inc VEEV $305.55 $337.04 +10% vs DRIO
HealthEquity, Inc HQY $103.54 $112.32 +8% vs DRIO
Waystar Holding WAY $29.30 $29.10 −1% vs DRIO
Tempus AI, Inc TEM $80.54 $52.58 −35% vs DRIO
HeartFlow, Inc HTFL $55.80 $34.82 −38% vs DRIO
Hinge Health, Inc HNGE $123.23 $51.25 −58% vs DRIO
Pro Medicus Limited PME A$207.31 A$85.12 −59% vs DRIO
BrightSpring Health Services, Inc BTSG $72.49 $25.72 −65% vs DRIO
XtalPi Holdings 2228 HK$6.37 HK$1.53 −76% vs DRIO

Explore undervalued stocks

More undervalued Healthcare stocks →

All undervalued stocks TechnologyFinancial ServicesHealthcareConsumer CyclicalConsumer DefensiveCommunication ServicesIndustrialsEnergyBasic MaterialsReal EstateUtilities Deeply Undervalued StocksUndervalued High-Quality StocksUndervalued Blue-Chip StocksUndervalued Small-Cap StocksUndervalued Dividend StocksUndervalued 52-Week Low StocksStocks for 2027: Large Companies Below Fair Value

Try a ready-made strategy

Pick a strategy and jump into the live analysis with that exact screen applied.

🥇 Backtested Best 🏆 Big Names 💎 Quality on Sale 🚀 Profitable Growth 🧊 Quality Compounders 💵 Dividend Stars 📈 Strong Momentum 📉 Fallen Angels ⚖️ Deeply Undervalued 🔍 Small-Cap Gems 🏰 Moat at a Fair Price 💼 Insider Buying 🎩 Buffett-Style Quality 📚 Peter Lynch GARP 🧮 Greenblatt Magic Formula 🛡️ Graham Defensive

Discover tools

Stock screenerFilter by region, size and sector Compare toolTwo stocks side by side Extrinsic Value Calculator…Free calculator Peter Lynch Fair Value Formula &…Free calculator
Run the numbers yourself: free valuation calculators
DCF CalculatorP/E Ratio CalculatorPEG Ratio CalculatorGraham NumberPeter Lynch FormulaDDM CalculatorIntrinsic ValueIntrinsic vs Extrinsic ValueP/E Ratio by Sector
For bloggers & editors: embed code + live data

For bloggers, editors and developers: paste this into your site or blog (a “Custom HTML” block in WordPress), it shows the current fair value and links back here. Free, plain HTML, and welcome. Full data streams (CSV/JSON) at /developers.

DarioHealth Corp: fair value per Fair Value Calculator

Cite: Fair Value Calculator (2026). "DarioHealth Corp Fair Value". https://www.fairvalue-calculator.com/stock/DRIO

Frequently asked questions

Is DarioHealth Corp (DRIO) overvalued or undervalued?
As of Nov 10, 2026, our estimate of fair value is $2.40 versus a price of $2.39, about +0% upside (fairly valued).
What is the fair value of DRIO?
Our estimate for DarioHealth Corp is $2.40 (as of Nov 10, 2026), built from audited fundamentals. The current price: $2.39.
What is the quality score of DRIO?
DarioHealth Corp has a Quality Score of 44/100. It measures business quality (profitability, growth, cash flow, balance-sheet strength, investment discipline, share issuance). Market factors such as price momentum and volatility do not enter the number; they are shown separately in the detail view.
What is the price target for DarioHealth Corp (DRIO)?
Our calculated price target is the estimate of $2.40 (as of Nov 10, 2026). Cautious scenario $1.80, optimistic scenario $2.99. It is an estimate from revenue and assets compared with similar companies, because none of our valuation models currently carries, not an analyst target.
What is the DarioHealth Corp stock forecast for 2026?
Our estimate puts fair value at $2.40, about +0% upside versus a price of $2.39 (fairly valued). Cautious scenario $1.80, optimistic scenario $2.99. The calculation is refreshed regularly with new filings.
What is the revenue of DarioHealth Corp (DRIO)?
DarioHealth Corp reported trailing-twelve-month revenue of about $21.0M (latest available figure, as of Nov 10, 2026).
What is the intrinsic value of DarioHealth Corp (DRIO)?
Intrinsic value and fair value mean the same thing: what the business is worth on its numbers, independent of the share price. For DarioHealth Corp it is $2.40 per share (as of Nov 10, 2026), against a price of $2.39.
Is DarioHealth Corp stock overvalued or undervalued in 2026?
As of Nov 10, 2026, DRIO trades below its calculated fair value: price $2.39, fair value $2.40, a gap of about +0% (fairly valued). The calculation is refreshed with each new quarterly report, so the verdict can change during the year.
Is fair value the same as the market price of DRIO?
No. The price is what the market pays today ($2.39); the fair value is what the company's own numbers justify ($2.40). For DarioHealth Corp the two are $0.0100 per share apart. That gap is exactly why we show both numbers side by side.
How much is DarioHealth Corp worth?
The market values DarioHealth Corp at about $32.4M (market capitalisation, as of Nov 10, 2026). Per share that is $2.39; our models calculate a fair value of $2.40 per share.
What do the bullish and bearish scenarios say about DRIO?
Our models span a range for DarioHealth Corp: cautious scenario $1.80, base $2.40, optimistic $2.99 per share (as of Nov 10, 2026, price $2.39). The range comes from different growth and margin assumptions, not from analyst opinions.
How solid is the balance sheet of DarioHealth Corp (DRIO)?
Balance-sheet figures for DarioHealth Corp (as of Nov 10, 2026): return on equity −59.9%, debt of 0.45 per unit of equity. They feed the Quality Score of 44/100, which measures business quality independently of the share price.
How far is DRIO from its 52-week high?
DarioHealth Corp trades at $2.39, about 83% below its 52-week high of $14.00 and 16% above the low of $2.06 (as of Nov 10, 2026). Distance from the high says nothing about value: that is what the fair value of $2.40 is for.
Which stocks are comparable to DarioHealth Corp?
From the same area (Healthcare) we also value Veeva Systems Inc, Pro Medicus Limited, BrightSpring Health Services, Inc, Tempus AI, Inc, among others. Each of them has its own fair-value calculation on this site using the same models, so the comparison is like for like.
Is DarioHealth Corp stock attractive at the current price?
The data as of Nov 10, 2026: price $2.39, calculated fair value $2.40 (+0%), Quality Score 44/100. Whether that fits your horizon and risk tolerance is your call. We provide the calculation, not investment advice.
Is it still worth investing in stocks now?
The global stock market currently sits 15.1% above its aggregate fair value. DarioHealth Corp itself currently trades above fair value. An expensive market is no reason to stay out and no reason to buy everything at once: keep a broad savings plan running, buy single stocks only with money you can do without, and hold part of your money liquid while the market is high. The full picture including sectors is on is it worth investing now.
What is the share price of DarioHealth Corp (DRIO)?
The closing price on Nov 10, 2026 was $2.39. Our estimate is $2.40, about +0% upside (fairly valued). We carry closing prices from our data provider, not a live tick.
What should I pay attention to with DarioHealth Corp right now?
The price sits close to our fair value, market and models broadly agree here, little valuation tension. Evidence is limited here (fewer models, shorter history), so the fair value is a rougher estimate than usual.

Key figures of DarioHealth Corp

How large is the market capitalisation of DarioHealth Corp (DRIO)?
The market capitalisation of DarioHealth Corp is $32.4M. The stock-market value of the whole company: share price times number of shares. It is what the market asks for the entire business today.
What is the P/S ratio of DarioHealth Corp (DRIO)?
The price-to-sales ratio of DarioHealth Corp is 1.54 (last twelve months). Price to sales: market value relative to yearly revenue. Useful when profit is thin or distorted.
What are the earnings per share of DarioHealth Corp (DRIO)?
Earnings per share at DarioHealth Corp are $−2.28. Earnings per share over the last twelve months: total profit spread across every single share.
What is the return on equity of DarioHealth Corp (DRIO)?
The return on equity (ROE) of DarioHealth Corp is −59.9% (last twelve months). Profit relative to shareholders' equity, how efficiently the company works with its owners' money.
What is the EBIT return on assets of DarioHealth Corp (DRIO)?
On an EBIT basis the return on assets of DarioHealth Corp is −52.7% (avg 5y). Operating profit (EBIT) relative to everything the company owns, as a multi-year average. It describes the business model rather than one good or bad year.
What is the operating margin of DarioHealth Corp (DRIO)?
The operating margin of DarioHealth Corp is −125% (last twelve months). Profit from the core business (before interest and taxes) relative to revenue.
How fast is revenue growing at DarioHealth Corp (DRIO)?
Revenue at DarioHealth Corp is growing −3.6% versus a year earlier (3y avg −6.8%). How much revenue grew versus a year earlier (YoY). The 3-year average next to it puts the single year in context.
How much free cash flow does DarioHealth Corp (DRIO) generate?
The free cash flow of DarioHealth Corp is −$26.1M (fiscal year 2025). The cash truly left after running and investing in the business, this is what pays dividends and buybacks.
How much net debt does DarioHealth Corp (DRIO) carry?
The net debt of DarioHealth Corp is $5.5M (fiscal year 2025). Debt minus cash on hand. The note shows how many years of free cash flow could in theory pay it off.
Free · no account needed

Watch DarioHealth Corp in the live analysis

One click puts DarioHealth Corp on your watchlist: fair value and trend at a glance, plus comparison, the diversification check and the 27,000+ stock screener.

Watch for free →

Zero risk: nothing is ever charged. Your watchlist is yours, with or without an account.